Celldex Therapeutics (CLDX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting held virtually, with reminders about forward-looking statements and SEC regulations.
Introduction of board members, auditors, and key executives in attendance.
Confirmation that only four proposals, as outlined in the proxy statement, would be considered.
Quorum established with over 65 million shares represented.
Board and executive committee updates
All current directors nominated for re-election, with motions and seconds for each proposal.
Shareholder proposals
Four proposals presented: election of directors, ratification of auditors, amendment to equity plan, and advisory vote on executive compensation.
No additional shareholder proposals were submitted in advance.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Celldex Therapeutics
- Q2 2026 net loss rose 30% as R&D spending surged, but liquidity remains strong through 2028.CLDX
Q2 2026 - No efficacy seen in prurigo nodularis; program discontinued, safety profile remains favorable.CLDX
Study result - Phase 2 and 52-week data in CSU and CIndU drive phase 3 launches and broad clinical expansion.CLDX
Guggenheim Securities Inaugural Healthcare Innovation Conference - Barzolvolimab delivers rapid, durable efficacy in CSU and ColdU, with strong financial backing.CLDX
Corporate presentation - Q1 2026 net loss rose 46% to $78.7M; $345M raised to fund operations through 2028.CLDX
Q1 2026 - Board recommends all proposals, with strong focus on pay-for-performance and ESG initiatives.CLDX
Proxy filing - Key data for PN, CSU, and AD expected in 2024, with commercial and pipeline advances underway.CLDX
TD Cowen 46th Annual Health Care Conference - Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4.CLDX
H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Barzolvolimab showed rapid, significant disease control in CIndU and is advancing to Phase 3.CLDX
Status Update